Sitagliptin Safety in Renal Impairment

Dosing Recommendations Based on Renal Function

The American College of Cardiology recommends sitagliptin dose adjustment in moderate to severe renal impairment, with normal to mild renal impairment (eGFR >50 mL/min/1.73 m²) requiring 100 mg daily, moderate renal impairment (eGFR 30-50 mL/min/1.73 m²) requiring 50 mg daily, and severe renal impairment (eGFR <30 mL/min/1.73 m²) requiring 25 mg daily 1, 3

Clinical studies involving patients with diabetes and chronic kidney disease have shown similar outcomes with sitagliptin as observed in patients without chronic kidney disease, with a low risk of hypoglycemia (6.2% vs 17.0%) 4, 5

Sitagliptin does not increase the risk of hypoglycemia when used alone, has a neutral effect on weight, and does not increase cardiovascular risk, making it a useful alternative to other antihyperglycemic medications 2, 3

The American Heart Association recommends assessing renal function before initiating sitagliptin and periodically thereafter, and monitoring for signs and symptoms of heart failure in patients with risk factors 1, 3
The American Diabetes Association recommends considering sitagliptin as a useful alternative to metformin in patients with chronic kidney disease, or in combination with metformin for additive effects in patients with less severe renal impairment 4, 5
The Endocrine Society recommends being vigilant for rare adverse effects such as pancreatitis, though causality has not been established 6, 3